Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Keneuoe Cecilia Nthontho, Andrew Khulekani Ndlovu, Kirthana Sharma, Ishmael Kasvosve, Daniel Louis Hertz & Giacomo Maria Paganotti. (2022) Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective. Pharmacogenomics and Personalized Medicine 15, pages 613-652.
Read now
Read now
Dora Janeth Fonseca, Adrien Morel, Kevin Llinás-Caballero, David Bolívar-Salazar & Paul Laissue. (2021) Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype. Pharmacogenomics and Personalized Medicine 14, pages 287-299.
Read now
Read now
Muhammad Suleman Khan, Daniel T. Barratt & Andrew A. Somogyi. (2016) Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib. Xenobiotica 46:3, pages 278-287.
Read now
Read now
Huijuan Wang, Raymond A. Kim, Dongxu Sun, Yiwen Gao, Hao Wang, Juanli Zhu & Chao Chen. (2011) Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay. Xenobiotica 41:9, pages 826-835.
Read now
Read now
Articles from other publishers (48)
Evelyn Incze, Katalin Mangó, Ferenc Fekete, Ádám Ferenc Kiss, Ádám Póti, Tünde Harkó, Judit Moldvay, Dávid Szüts & Katalin Monostory. (2023) Potential Association of Cytochrome P450 Copy Number Alteration in Tumour with Chemotherapy Resistance in Lung Adenocarcinoma Patients. International Journal of Molecular Sciences 24:17, pages 13380.
Crossref
Crossref
Yitian Zhou & Volker M. Lauschke. (2022) The genetic landscape of major drug metabolizing cytochrome P450 genes—an updated analysis of population-scale sequencing data. The Pharmacogenomics Journal 22:5-6, pages 284-293.
Crossref
Crossref
Diana María Campodónico, Pablo Zubiaur, Paula Soria‐Chacartegui, Ana Casajús, Gonzalo Villapalos‐García, Marcos Navares‐Gómez, Antía Gómez‐Fernández, Raúl Parra‐Garcés, Gina Mejía‐Abril, Manuel Román, Samuel Martín‐Vílchez, Dolores Ochoa & Francisco Abad‐Santos. (2022)
CYP2C8
*3 and *4 define
CYP2C8
phenotype: An approach with the substrate cinitapride
. Clinical and Translational Science 15:11, pages 2613-2624.
Crossref
Crossref
Mariangela Lattanzio, Marco Ferrari, Stefano Martini, Francesca Ceriani, Andrea Imporzani, Franca Marino, Roberto De Ponti & Marco Cosentino. (2022) Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: a case report . Journal of Medical Case Reports 16:1.
Crossref
Crossref
Shalini Roy Chowdhury, Oindrilla Dutta Gupta, Arnab Kumar Ghosh, Partha Sarathi Singha, Syed Benazir Firdaus & Klaus Klarskov. (2021) Genetic variations and epigenetic modulations in CYP genes: Implications in NSAID-treatment of arthritis patients. The Nucleus 64:3, pages 331-342.
Crossref
Crossref
Thomas Helland, Sarah Alsomairy, Chenchia Lin, Håvard Søiland, Gunnar Mellgren & Daniel Louis Hertz. (2021) Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer. Journal of Personalized Medicine 11:3, pages 201.
Crossref
Crossref
Mailys De Sousa Mendes, Oliver Hatley, Katherine Linda Gill, Karen Rowland Yeo & Alice Ban Ke. (2020) A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients. European Journal of Pharmaceutical Sciences 150, pages 105355.
Crossref
Crossref
N. A. Shnayder, E. N. Bochanova, D. V. Dmitrenko & R. F. Nasyrova. (2020) Pharmacogenetics of carbamazepine. Epilepsy and paroxysmal conditions 11:4, pages 364-378.
Crossref
Crossref
Leda Marina Pomes, Martina Guglielmetti, Enrico Bertamino, Maurizio Simmaco, Marina Borro & Paolo Martelletti. (2019) Optimising migraine treatment: from drug-drug interactions to personalized medicine. The Journal of Headache and Pain 20:1.
Crossref
Crossref
William R. Arnold, Susan Zelasko, Daryl D. Meling, Kimberly Sam & Aditi Das. (2019) Polymorphisms of CYP2C8 Alter First-Electron Transfer Kinetics and Increase Catalytic Uncoupling. International Journal of Molecular Sciences 20:18, pages 4626.
Crossref
Crossref
Lauren A Marcath, Kelley M Kidwell, Adam C Robinson, Kiran Vangipuram, Monika L Burness, Jennifer J Griggs, Catherine Van Poznak, Anne F Schott, Daniel F Hayes, Norah Lynn Henry & Daniel L Hertz. (2019)
Patients carrying
CYP2C8*3
have shorter systemic paclitaxel exposure
. Pharmacogenomics 20:2, pages 95-104.
Crossref
Crossref
Joseph D. Tucci, Paul P. Pumuye, Nuala A. Helsby, Daniel T. Barratt, Percy P. Pokeya, Francis Hombhanje & Andrew A. Somogyi. (2018) Pharmacogenomics in Papua New Guineans. Pharmacogenetics and Genomics 28:6, pages 153-164.
Crossref
Crossref
Pil Joung Cho, WoongShik Nam, Doohyun Lee, Taeho Lee & Sangkyu Lee. (2018) Selective Inhibitory Effect of Osthenol on Human Cytochrome 2C8. Bulletin of the Korean Chemical Society 39:6, pages 801-805.
Crossref
Crossref
Thomas M. Polasek, Geoffrey T. Tucker, Michael J. Sorich, Michael D. Wiese, Titus Mohan, Amin Rostami-Hodjegan, Porntipa Korprasertthaworn, Vidya Perera & Andrew Rowland. (2018) Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. British Journal of Clinical Pharmacology 84:3, pages 462-476.
Crossref
Crossref
Katarzyna E. Lazarska, Stefan J. Dekker, Nico P.E. Vermeulen & Jan N.M. Commandeur. (2018) Effect of UGT2B7*2 and CYP2C8*4 polymorphisms on diclofenac metabolism. Toxicology Letters 284, pages 70-78.
Crossref
Crossref
Kenta Haraya, Motohiro Kato, Koji Chiba & Yuichi Sugiyama. (2017) Prediction of inter-individual variability on the pharmacokinetics of CYP2C8 substrates in human. Drug Metabolism and Pharmacokinetics 32:6, pages 277-285.
Crossref
Crossref
Natasa Djordjevic, Slobodan M. Jankovic & Jasmina R. Milovanovic. (2017) Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children. European Journal of Drug Metabolism and Pharmacokinetics 42:5, pages 729-744.
Crossref
Crossref
Alexey Polonikov, Alexander Kharchenko, Marina Bykanova, Svetlana Sirotina, Irina Ponomarenko, Anna Bocharova, Kseniya Vagaytseva, Vadim Stepanov, Olga Bushueva, Mikhail Churnosov & Maria Solodilova. (2017) Polymorphisms of CYP2C8 , CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population. Gene 627, pages 451-459.
Crossref
Crossref
Daniel T. Barratt, Hannah K. Cox, Andrew Menelaou, David T. Yeung, Deborah L. White, Timothy P. Hughes & Andrew A. Somogyi. (2016) CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients. Clinical Pharmacokinetics 56:8, pages 977-985.
Crossref
Crossref
Michiel C. Verboom, Loes Visser, Sander Kouwen, Jesse J. Swen, Jeroen Diepstraten, Ward F. Posthuma, Hans Gelderblom, Daniëlle van Lammeren & Erik B. Wilms. (2017) Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients. Pharmacogenetics and Genomics 27:6, pages 223-226.
Crossref
Crossref
Adriana Isvoran, Maxime Louet, Diana Larisa Vladoiu, Dana Craciun, Marie-Anne Loriot, Bruno O. Villoutreix & Maria A. Miteva. (2017) Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. Drug Discovery Today 22:2, pages 366-376.
Crossref
Crossref
Delisha A. Stewart, Jason H. Winnike, Susan L. McRitchie, Robert F. Clark, Wimal W. Pathmasiri & Susan J. Sumner. (2016) Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences. Journal of Proteome Research 15:9, pages 3225-3240.
Crossref
Crossref
Yuji Mukai, Asuna Senda, Takaki Toda, Erik Eliasson, Anders Rane & Nobuo Inotsume. (2016) The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes. Basic & Clinical Pharmacology & Toxicology 118:6, pages 408-414.
Crossref
Crossref
Valon Krasniqi, Aleksandar Dimovski, Iva Klarica Domjanović, Ivan Bilić & Nada Božina. (2016) How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity / Kako polimorfizmi gena citokroma P450 utječu na metabolizam i toksičnost ibuprofena i diklofenaka. Archives of Industrial Hygiene and Toxicology 67:1, pages 1-8.
Crossref
Crossref
Janne T. Backman, Anne M. Filppula, Mikko Niemi & Pertti J. Neuvonen. (2015) Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacological Reviews 68:1, pages 168-241.
Crossref
Crossref
Kohei Fujikura, Magnus Ingelman-Sundberg & Volker M. Lauschke. (2015) Genetic variation in the human cytochrome P450 supergene family. Pharmacogenetics and Genomics 25:12, pages 584-594.
Crossref
Crossref
Renata Szalai, Alma Ganczer, Lili Magyari, Petra Matyas, Judit Bene & Bela Melegh. (2015) Interethnic differences of cytochrome P450 gene polymorphisms may influence outcome of taxane therapy in Roma and Hungarian populations. Drug Metabolism and Pharmacokinetics 30:6, pages 453-456.
Crossref
Crossref
Chiharu Tsukada, Takahiro Saito, Masamitsu Maekawa, Nariyasu Mano, Akifumi Oda, Noriyasu Hirasawa & Masahiro Hiratsuka. (2015) Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation. Drug Metabolism and Pharmacokinetics 30:5, pages 366-373.
Crossref
Crossref
Mi-Young Lee, María Apellániz-Ruiz, Inger Johansson, Svante Vikingsson, Troels K Bergmann, Kim Brøsen, Henrik Green, Cristina Rodríguez-Antona & Magnus Ingelman-Sundberg. (2015)
Role of cytochrome P450
2C8*3
(
CYP2C8*3
) in paclitaxel metabolism and paclitaxel-induced neurotoxicity
. Pharmacogenomics 16:9, pages 929-937.
Crossref
Crossref
Dolores Ochoa, Rocío Prieto-Pérez, Manuel Román, María Talegón, Angela Rivas, Ignacio Galicia, Francisco Abad-Santos & Teresa Cabaleiro. (2015)
Effect of gender and
CYP2C9
and
CYP2C8
polymorphisms on the pharmacokinetics of ibuprofen enantiomers
. Pharmacogenomics 16:9, pages 939-948.
Crossref
Crossref
Faraz Kazmi, Joanna E. Barbara, Phyllis Yerino & Andrew Parkinson. (2015) A Long-Standing Mystery Solved: The Formation of 3-Hydroxydesloratadine Is Catalyzed by CYP2C8 But Prior Glucuronidation of Desloratadine by UDP-Glucuronosyltransferase 2B10 Is an Obligatory Requirement. Drug Metabolism and Disposition 43:4, pages 523-533.
Crossref
Crossref
Mark K Donnelly, Yvette P Conley, Elizabeth A Crago, Dianxu Ren, Paula R Sherwood, Jeffery R Balzer & Samuel M Poloyac. (2014) Genetic Markers in the EET Metabolic Pathway Are Associated with Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage. Journal of Cerebral Blood Flow & Metabolism 35:2, pages 267-276.
Crossref
Crossref
F. Peter Guengerich. 2015. Cytochrome P450. Cytochrome P450
523
785
.
William D. Simmons, Pamala A. Jacobson & Karen L. Hardinger. 2014. Textbook of Organ Transplantation. Textbook of Organ Transplantation
1242
1255
.
Zhangting Wang, Shengjia Wang, Minmin Huang, Haihong Hu, Lushan Yu & Su Zeng. (2014) Characterizing the Effect of Cytochrome P450 (CYP) 2C8, CYP2C9, and CYP2D6 Genetic Polymorphisms on Stereoselective N-demethylation of Fluoxetine. Chirality 26:3, pages 166-173.
Crossref
Crossref
Christina L. Aquilante, Mikko Niemi, Li Gong, Russ B. Altman & Teri E. Klein. (2013) PharmGKB summary. Pharmacogenetics and Genomics 23:12, pages 721-728.
Crossref
Crossref
Christina L. Aquilante, Michael F. Wempe, Samantha H. Spencer, Lisa A. Kosmiski, Julie A. Predhomme & Maha S. Sidhom. (2013)
Influence of
CYP2C8*2
on the Pharmacokinetics of Pioglitazone in Healthy African-American Volunteers
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33:9, pages 1000-1007.
Crossref
Crossref
Lushan Yu, Da Shi, Liping Ma, Quan Zhou & Su Zeng. (2013)
Influence of
CYP2C8
polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers
in vitro
. Biopharmaceutics & Drug Disposition 34:5, pages 278-287.
Crossref
Crossref
Feng You, Jinping Hu, Xue Li & Yan Li. (2013) The elimination of MTC-220, a novel anti-tumor agent of conjugate of paclitaxel and muramyl dipeptide analogue, in rats. Cancer Chemotherapy and Pharmacology 71:6, pages 1453-1462.
Crossref
Crossref
Karen Rowland Yeo, Jane R. Kenny & Amin Rostami-Hodjegan. (2013) Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. European Journal of Clinical Pharmacology 69:6, pages 1311-1320.
Crossref
Crossref
Ulrich M. Zanger & Matthias Schwab. (2013) Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics 138:1, pages 103-141.
Crossref
Crossref
Teresa Cabaleiro, Manuel Román, Dolores Ochoa, María Talegón, Rocío Prieto-Pérez, Aneta Wojnicz, Rosario López-Rodríguez, Jesús Novalbos & Francisco Abad-Santos. (2013)
Evaluation of the Relationship between Sex, Polymorphisms in
CYP2C8
and
CYP2C9
, and Pharmacokinetics of Angiotensin Receptor Blockers
. Drug Metabolism and Disposition 41:1, pages 224-229.
Crossref
Crossref
Daniel L. Hertz, Alison A. Motsinger-Reif, Amy Drobish, Stacey J. Winham, Howard L. McLeod, Lisa A. Carey & E. Claire Dees. (2012) CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Research and Treatment 134:1, pages 401-410.
Crossref
Crossref
Chia Yong Pang, Joon Wah Mak, Rusli Ismail & Chin Eng Ong. (2012) In vitro modulatory effects of flavonoids on human cytochrome P450 2C8 (CYP2C8). Naunyn-Schmiedeberg's Archives of Pharmacology 385:5, pages 495-502.
Crossref
Crossref
Rüdiger Kaspera, Suresh B. Naraharisetti, Eric A. Evangelista, Kristin D. Marciante, Bruce M. Psaty & Rheem A. Totah. (2011) Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochemical Pharmacology 82:6, pages 681-691.
Crossref
Crossref
Huijuan Wang, Nianzhen An, Hao Wang, Yiwen Gao, Duan Liu, Ting Bian, Juanli Zhu & Chao Chen. (2011)
Evaluation of the Effects of 20 Nonsynonymous Single Nucleotide Polymorphisms of CYP2C19 on
S
-Mephenytoin 4′-Hydroxylation and Omeprazole 5′-Hydroxylation
. Drug Metabolism and Disposition 39:5, pages 830-837.
Crossref
Crossref
Tomohiro Kaku, Nobuyuki Matsunaga, Akio Ojida, Toshimasa Tanaka, Takahito Hara, Masuo Yamaoka, Masami Kusaka & Akihiro Tasaka. (2011) 17,20-Lyase inhibitors. Part 4: Design, synthesis and structure–activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors. Bioorganic & Medicinal Chemistry 19:5, pages 1751-1770.
Crossref
Crossref
Duan Liu, Yiwen Gao, Huijuan Wang, Jing Zi, He Huang, Jing Ji, Ruimin Zhou, Yefei Nan, Shixiang Wang, Xiaohui Zheng, Juanli Zhu, Yali Cui & Chao Chen. (2010) Evaluation of the Effects of Cytochrome P450 Nonsynonymous Single-Nucleotide Polymorphisms on Tanshinol Borneol Ester Metabolism and Inhibition Potential. Drug Metabolism and Disposition 38:12, pages 2259-2265.
Crossref
Crossref